Multi-Omics Study Reveals Proteogenomic Signature of High-Risk Diffuse Large B-Cell Lymphoma
核心洞察
An international team analyzed tumor samples from 478 DLBCL patients using combined genetic, proteomic, and AI-driven approaches to identify novel molecular subtypes beyond genetics alone.
High-risk patients classified as proteogenotype 4 (PG4) exhibit MYC (搜索)-driven tumor biology and immunologically "cold" tumors with suppressed cytotoxic T-cell function.
Experimental pharmacological inhibition of MYC (搜索)-related molecular programs selectively eliminated PG4 lymphoma cells in culture, pointing to potential therapeutic targets.
An international research team led by Goethe University Frankfurt (搜索) and Universitätsmedizin Frankfurt (搜索) has uncovered novel biological characteristics that distinguish particularly aggressive forms of diffuse large B-cell lymphoma (搜索) (DLBCL), offering a path toward earlier identification of high-risk patients and more precisely tailored therapies. The findings, published in Cancer Cell, integrate genetic mutations, gene expression, and proteomic data from 478 patient tumor samples using machine learning to reveal tumor features that transcend previously established genetic classification systems.
With more than 150,000 new cases worldwide each year, DLBCL is the most common aggressive form of lymphoma. Standard first-line treatment with a therapeutic antibody combined with chemotherapy — either R-CHOP (搜索) or Pola-R-CHP (搜索) — cures nearly two-thirds of patients. Yet more than one-third experience relapse or have tumors that fail to respond, necessitating alternative approaches such as CAR T-cell therapy. This variability in treatment response has long been attributed to the considerable molecular heterogeneity of the disease.
Integrating Multiple Molecular Layers with AI
While DLBCL has been extensively characterized at the genetic level, yielding classification systems based on genetic alterations and gene expression patterns, the Frankfurt-led team sought to go further. Researchers analyzed tumor samples by examining mutations, gene expression, and — critically — the identity and quantity of proteins produced in tumor cells through proteomic analysis.
These multi-layered datasets were then evaluated using artificial intelligence models developed by the team of Professor Florian Büttner from the Faculty of Medicine and the Institute of Computer Science at Goethe University Frankfurt (搜索). "Our model demonstrates how interpretable machine learning can reveal relationships across different molecular layers: we succeeded in correlating mutation and protein patterns with treatment outcomes," Büttner explained. The approach enabled the classification of patients into groups that both describe disease biology and provide insights into potential therapeutic options. Findings were subsequently validated using high-resolution single-cell tumor analyses.
The PG4 High-Risk Signature: MYC (搜索)-Driven and Immunologically Cold
Dr. Julius Enssle, a physician-scientist at Universitätsmedizin Frankfurt (搜索) and the National Institutes of Health in the United States, who served as one of the study's three first authors alongside biochemist Dr. Björn Häupl and computer scientist Arber Qoku, described the clinical implications: "We can now much better understand the biological characteristics of DLBCL tumors that determine patients' clinical prognosis and are independent of previously established risk factors."
The study identified a high-risk subgroup designated as proteogenotype 4 (PG4), whose tumors are centered around the MYC (搜索) gene, which drives tumor cell growth and division. Critically, these tumors exhibit an immunologically "cold" microenvironment with very few infiltrating immune cells. "The tumors of high-risk patients are immunologically 'cold' — in particular, the function of cytotoxic T cells is suppressed, which normally recognize and eliminate tumor cells," Enssle noted.
Importantly, the data demonstrated that different genetic mutations can converge on similar tumor cell characteristics in DLBCL, providing a clearer mechanistic understanding of how diverse mutational landscapes produce comparable aggressive phenotypes.
Toward Precision Therapeutics
Building on these molecular insights, the research team successfully inhibited the MYC (搜索)-driven molecular programs in cultured PG4 lymphoma cells using pharmacological approaches, selectively eliminating the lymphoma cells. "This has enabled us to identify potential targets for the development of precision diagnostics and therapies," Enssle stated.
Professor Thomas Oellerich, Director of the Department of Medicine 2 at Universitätsmedizin Frankfurt (搜索) and lead investigator of the study, offered a measured but optimistic outlook: "Although there is still a long way to go, we have taken an important step toward personalized medicine for aggressive lymphoma. In the long term, our findings may help identify high-risk patients earlier and tailor their treatment more precisely to the underlying tumor biology."
The study represents a collaboration spanning Goethe University Frankfurt (搜索), Universitätsmedizin Frankfurt (搜索), the German Cancer Consortium (DKTK), the Frankfurt Cancer Institute, and multiple international institutions including the National Institutes of Health.